| # | Drug | Count |
|---|---|---|
| 0 | HUMAN IMMUNOGLOBULIN G | 89 |
| 1 | RITUXIMAB | 45 |
| 2 | METHOTREXATE SODIUM | 42 |
| 3 | METHOTREXATE | 36 |
| 4 | PREDNISONE | 35 |
| 5 | ADALIMUMAB | 26 |
| 6 | CYCLOPHOSPHAMIDE | 24 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 24 |
| 8 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 24 |
| 9 | INFLIXIMAB | 24 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PLATINUM | 15 | 0.0282 |
| 1 | DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE | 2 | 0.0064 |
| 2 | HUMAN IMMUNOGLOBULIN G | 89 | 0.0043 |
| 3 | PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION | 3 | 0.0025 |
| 4 | ADEFOVIR DIPIVOXIL | 3 | 0.0024 |
| 5 | BETAXOLOL HYDROCHLORIDE | 1 | 0.0019 |
| 6 | PILOCARPINE HYDROCHLORIDE | 4 | 0.0016 |
| 7 | PYRIDOSTIGMINE BROMIDE ORAL | 5 | 0.0014 |
| 8 | ISONIAZID | 20 | 0.0012 |
| 9 | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | 6 | 0.0009 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 62 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 54 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 44 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 42 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 36 |
| 5 | Alkylating Drug [EPC] | 24 |
| 6 | Antirheumatic Agent [EPC] | 23 |
| 7 | Interleukin-6 Receptor Antagonist [EPC] | 22 |
| 8 | Antimycobacterial [EPC] | 21 |
| 9 | Aminosalicylate [EPC] | 20 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antimycobacterial [EPC] | 21 | 0.0009 |
| 1 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 2 | Human Immunoglobulin G [EPC] | 9 | 0.0004 |
| 3 | Cytomegalovirus pUL97 Kinase Inhibitor [EPC] | 1 | 0.0004 |
| 4 | Bismuth [EPC] | 2 | 0.0004 |
| 5 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 6 | Antirheumatic Agent [EPC] | 23 | 0.0002 |
| 7 | Topoisomerase Inhibitor [EPC] | 16 | 0.0002 |
| 8 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 10 | 0.0002 |
| 9 | Aminosalicylate [EPC] | 20 | 0.0002 |